Pipeline

Program Indication Research Preclinical Phase 1 Phase 2 Phase 3
Efzofitimod
(ATYR1923)
Pulmonary Sarcoidosis(1)

 

SSc-ILD(2)

 

Other ILD
(CTD-ILD; CHP)(3)

 

ATYR2810 Solid Tumors

 

NRP2 mAbs Inflammation

 

AARS-1; DARS‑1(4) Fibrosis; Inflammation; Cancer

 

Program Target Phase
Efzofitimod (ATYR1923) Pulmonary Sarcoidosis(1) Phase 3
SSc-ILD(2) Phase 1
Other ILD (CTD-ILD; CHP)(3) Phase 1
ATYR2810 Solid Tumors Preclinical
NRP2 mAbs Inflammation Research
AARS-1; DARS‑1(4) Fibrosis; Inflammation; Cancer Research

(1) In partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILD in Japan
(2) SSc-ILD: Scleroderma-related ILD
(3) CTD-ILD: Connective Tissue Disease-ILD; CHP: Chronic Hypersensitivity Pneumonitis
(4) The next two candidates from our tRNA synthetase platform